Navigation Links
Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection

Sangamo BioSciences, Inc. today announced that data from its program to develop a ZFP Therapeutic for HIV/AIDS were presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. The study represents the first demonstration that cells can be made resistant to HIV infection by treatment with Sangamo's proprietary zinc finger DNA-binding protein nucleases (ZFNTM) designed to specifically disrupt the CCR5 gene.

In its anti-HIV preclinical research program, Sangamo has designed ZFNs that can be used to disrupt the CCR5 gene, a receptor required for HIV entry into immune cells. The researchers found that ZFN-modified cells were resistant to HIV infection whereas control cells were infected when challenged with the virus. Furthermore, when CCR5 expression was experimentally restored in the ZFN-modified cells, HIV was once again able to infect these cells. Sangamo has shown disruption of the CCR5 gene in a number of different cell types including T-cells, the target cell for this therapeutic approach.

"CCR5 is an important target in the fight against HIV/AIDS," stated Edward Lanphier, Sangamo's president and CEO. "Individuals with a natural mutation of their CCR5 gene have been shown to be resistant to HIV infection. Several major pharmaceutical companies have initiated programs to develop small molecule drugs to block HIV binding to CCR5, but in recent months two trials have been halted, one due to reports of liver toxicity of the candidate drug. We believe that using ZFNs to permanently modify the CCR5 gene specifically in T-cells and thus directly block the expression of the protein on the surface of these cells may have several advantages over the systemic effects of other drugs in development."

Small molecule or antibody approaches require the constant presence of antagonist in high enough concentrations to block therapeutically relevant numbers of the CCR5 protein, of which there
'"/>

Source:jjackson@burnsmc.com


Page: 1 2

Related biology news :

1. MRSA study demonstrates need for frequent hand washing and environmental disinfection in health care settings
2. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
3. Xie Lab demonstrates the role of microRNA pathway
4. Protein discovery could unlock the secret to better TB treatment
5. Topical treatment shown to inhibit HIV and herpes simplex virus infection
6. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
7. Researchers add new tool to tumor-treatment arsenal
8. Potential treatments for neurofibromatosis
9. Nanoparticles offer new hope for detection and treatment
10. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
11. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
Post Your Comments:
(Date:7/31/2014)... have completed a 20-year study that looks at ... different times of the year. It finds that ... frame has no measurable negative consequences for the ... , The study was conducted by Gene Towne, ... fire chief, and Joseph Craine, research assistant professor, ...
(Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
(Date:7/31/2014)... Edmond Becquerel first discovered the photovoltaic effect in 1839, ... power of sunlight for its own purposes. In a ... of the FASEB Journal , scientists ... power of sunlight by focusing on a naturally occurring ... evolution. This conservationor persistence over time and across speciessuggests ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists shine bright new light on how living things capture energy from the sun 2
... that previously unrecognized substances released by algae blooms have ... interfere with the normal activity of reproductive hormones. The ... as potentially harmful to humans and aquatic animals, but ... are calling for a revision of environmental monitoring programs ...
... the establishment of the Jeffrey Modell Endowed Chair in ... at the Hospital,s Ruth and Tristram Colket, Jr. Translational ... pediatric immunologist Jordan S. Orange, M.D., Ph.D. The chair,s ... new ground in his ongoing research. Dr. Orange is ...
... the brain are characteristic features of Alzheimer disease. The ... that plays a central role in learning and memory, ... effect of tau protein is largely eliminated when the ... Max Planck Research Unit for Structural Molecular Biology at ...
Cached Biology News:Modell Chair in Pediatric Immunology established 2Tau-induced memory loss in Alzheimer's mice is reversible 2Tau-induced memory loss in Alzheimer's mice is reversible 3
(Date:7/31/2014)... Toronto, Canada (PRWEB) July 31, 2014 ... with some of the first transcriptome-wide analyses appearing ... a standard assay for RNA measurement. In the ... high throughput, more specific, work with smaller input ... special tissues (eg, blood samples). On the bioinformatics ...
(Date:7/31/2014)... Miami, Fla. (PRWEB) July 31, 2014 The ... for distribution of its monthly news magazine, Kidney Cancer News. ... have a presence on a website maintained by an international ... noted an immediate increase in viewers.” , This month’s program ... of kidney tumors analyzed in a recent study. Kidney ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)...  The Chicago Bears are excited to announce the ... in an effort to raise awareness of skin cancer. ... SPOT me™ skin cancer screenings at a preseason fan ... SPOT me™ is an educational campaign designed to inform ... of skin cancer, and encourages people to get screened ...
Breaking Biology Technology:The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... N.Y., Sept. 5 BioSpecifics,Technologies Corp. (OTC Bulletin ... collagenase based products, announced today that,it has signed ... related,to its future royalty obligations for Peyronie,s disease ... one-time cash payment., BioSpecifics has modified its ...
... 4 Hologic, Inc.,(Nasdaq: HOLX ) today announced ... the Morgan Stanley Global Healthcare Unplugged,Conference being held September ... NY., Interested parties are invited to listen to ... September 9, 2008, at 1:35 PM.,Eastern Time on the ...
... COLLINS, Colo., Sept. 4 InVitria,( ... of animal free,products that enhance productivity, ... companies,in the biopharmaceutical, cell culture, life ... Sponsorship of Cambridge Healthtech,Institute,s 4th Annual ...
Cached Biology Technology:BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Form: Concentrated Applications: ELISA...
Biology Products: